Status: Recruiting
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
Participants needed: 330
Trial details
Phase: Phase 2Age: 9-45Biological sex: AllType: InterventionalSponsor: Shanghai Bovax Biotechnology Co., Ltd.Updated: Dec 17, 2025Locations: 1
Eligibility criteria
Participants aged 9-45； [+6]
Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV v... [+18]